Display options
Cite
Ye Z, Zhang X, Luo Y, et al. Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases. PLoS One. 2016;11(9):e0163162doi: 10.1371/journal.pone.0163162.
Ye, Z., Zhang, X., Luo, Y., Li, S., Huang, L., Li, Z., Li, P., & Chen, G. (2016). Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases. PloS one, 11(9), e0163162. https://doi.org/10.1371/journal.pone.0163162
Ye, Zhihua, et al. "Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases." PloS one vol. 11,9 (2016): e0163162. doi: https://doi.org/10.1371/journal.pone.0163162
Ye Z, Zhang X, Luo Y, Li S, Huang L, Li Z, Li P, Chen G. Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases. PLoS One. 2016 Sep 22;11(9):e0163162. doi: 10.1371/journal.pone.0163162. eCollection 2016. PMID: 27657690; PMCID: PMC5033348.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2016 Sep 22;11(9):e0163162. doi: 10.1371/journal.pone.0163162. eCollection 2016.

Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases.

PloS one

Zhihua Ye, Xin Zhang, Yihuan Luo, Shikang Li, Lanshan Huang, Zuyun Li, Ping Li, Gang Chen

Affiliations

  1. Department of Pathology, First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China.
  2. Department of Thoracic and Cardiovascular Surgery, First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China.

PMID: 27657690 PMCID: PMC5033348 DOI: 10.1371/journal.pone.0163162

Abstract

BACKGROUND: Vimentin is a member of the intermediate filament proteins and a canonical marker of the epithelial-mesenchymal transition (EMT), which is pivotal in tumorigenesis, metastasis and invasion in non-small cell lung cancer (NSCLC). The current meta-analysis aimed to investigate the associations between vimentin and prognosis and progression in NSCLC.

METHODS: Databases with literature published in English, including PubMed, Web of Science, Embase, Science Direct, Wiley Online Library, Ovid, Cochrane Central Register of Controlled Trials, LILACS and Google Scholar, and the CNKI, VIP, CBM and WanFang databases in Chinese were used for the literature search. The key terms included (1) 'vimentin' OR 'vim' OR 'vmt' OR 'vm' OR 'hel113' OR 'ctrct30' and (2) 'pulmon*' OR 'lung' OR 'alveolar' and (3) 'cancer' OR 'carcinoma' OR 'tumor' OR 'adenocarcinoma' OR 'squamous' OR 'neoplas*' OR 'malignan*'. The data were combined by random effect model and the H value and I2 were used to assess the heterogeneity. All the meta-analysis was conducted using Stata 12.0.

RESULTS: Thirty-two qualified studies (4118 cases) were included in the current meta-analysis. Twelve studies with 1750 patients were included to assess the significance of vimentin in the overall survival (OS) of NSCLC; the pooled hazard ratio (HR) was 1.831 (confidence interval (CI): 1.315-2.550, P<0.001) in the univariate analysis and 1.266 (CI: 0.906-1.768, P = 0.167) in the multivariate analysis. Four studies with 988 cases were applicable to determine the significance of vimentin in the disease-free survival (DFS) of NSCLC; the pooled HR of the DFS was 1.224 (CI: 0.921-1.628, P = 0.164) in the univariate analysis and 1.254 (CI: 0.985-1.956, P = 0.067) in the multivariate analysis. Regarding the relationships between vimentin and clinicopathological factors, the pooled odds ratio (OR) with 3406 NSCLCs indicated that up-regulated vimentin was associated with smoking (OR = 1.359, CI: 1.098-1.683, P = 0.004), poor differentiation (OR = 2.133, CI: 1.664-2.735, P<0.001), an advanced TNM stage (OR = 3.275, CI: 1.987-5.397, P<0.001), vascular invasion (OR = 3.492, CI: 1.063-11.472, P = 0.039), lymph node metastasis (OR = 2.628, CI: 1.857-3.718, P<0.001), recurrence (OR = 1.631, CI: 1.052-2.528, P = 0.029) and pleural invasion (OR = 2.346, CI: 1.397-3.941, P = 0.001). There was no significant correlation between vimentin and age, gender, diameter, T stage, distant metastasis, or marginal invasion (P>0.05).

CONCLUSION: An overexpression of vimentin may predict the progression and an unfavorable survival of NSCLC. Vimentin may represent a helpful biomarker and a potential target for the treatment strategies of NSCLC. Additional, prospective studies with large samples are necessary to confirm the significance of vimentin in NSCLC.

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Chin J Cancer Res. 2014 Feb;26(1):48-58 - PubMed
  2. Int J Clin Exp Pathol. 2015 Aug 01;8(8):8997-9009 - PubMed
  3. BMJ. 2007 Nov 3;335(7626):914-6 - PubMed
  4. Anticancer Res. 2011 Dec;31(12):4451-6 - PubMed
  5. Stat Med. 2006 Dec 30;25(24):4321-33 - PubMed
  6. Stat Med. 2001 Mar 30;20(6):825-40 - PubMed
  7. Stat Med. 1998 Apr 30;17(8):841-56 - PubMed
  8. Lung Cancer. 2013 Jul;81(1):117-22 - PubMed
  9. Oncol Rep. 2014 Jun;31(6):2660-8 - PubMed
  10. BMC Cancer. 2013 Mar 27;13:158 - PubMed
  11. Mol Med Rep. 2014 Nov;10 (5):2575-9 - PubMed
  12. Stat Med. 1998 Dec 30;17(24):2815-34 - PubMed
  13. Stat Methods Med Res. 2012 Aug;21(4):409-26 - PubMed
  14. Respirology. 2015 Apr;20(3):370-8 - PubMed
  15. Pathol Int. 2015 Apr;65(4):183-92 - PubMed
  16. Korean J Pathol. 2013 Feb;47(1):44-51 - PubMed
  17. Clin Cancer Res. 2008 Nov 15;14(22):7430-7 - PubMed
  18. Zhonghua Zhong Liu Za Zhi. 2011 Aug;33(8):590-3 - PubMed
  19. Clin Transl Oncol. 2014 Feb;16(2):178-83 - PubMed
  20. Respirology. 2012 Oct;17(7):1048-59 - PubMed
  21. Histol Histopathol. 2012 May;27(5):581-91 - PubMed
  22. Respirology. 2009 Apr;14(3):371-6 - PubMed
  23. PLoS One. 2013 Jul 26;8(7):e69930 - PubMed
  24. Int J Clin Exp Pathol. 2014 Aug 15;7(9):5846-54 - PubMed
  25. J Clin Pathol. 2013 Nov;66(11):937-45 - PubMed
  26. Am J Respir Cell Mol Biol. 2014 Jan;50(1):1-6 - PubMed
  27. J Clin Epidemiol. 2000 Nov;53(11):1119-29 - PubMed
  28. Tumour Biol. 2015 Aug;36(8):6559-68 - PubMed
  29. World J Surg Oncol. 2015 Aug 01;13:234 - PubMed
  30. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  31. CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71 - PubMed
  32. BMC Cancer. 2015 Mar 08;15:107 - PubMed
  33. Asian Pac J Cancer Prev. 2014;15(9):4013-8 - PubMed
  34. Clin Transl Med. 2015 Feb 26;4:6 - PubMed
  35. Cell Mol Life Sci. 2011 Sep;68(18):3033-46 - PubMed
  36. Anticancer Res. 2012 Feb;32(2):537-52 - PubMed
  37. PLoS One. 2012;7(6):e39937 - PubMed
  38. BMC Med. 2013 Jul 19;11:168 - PubMed
  39. Toxicol Sci. 2013 Oct;135(2):265-76 - PubMed
  40. Med Oncol. 2012 Sep;29(3):1606-13 - PubMed
  41. Drugs Today (Barc). 2014 Jul;50(7):503-25 - PubMed
  42. Cancer Med. 2015 Dec;4(12 ):1853-62 - PubMed
  43. Biosci Trends. 2013 Dec;7(6):264-9 - PubMed
  44. Can J Surg. 2001 Jun;44(3):180-8 - PubMed
  45. Oncotarget. 2015 Nov 17;6(36):38705-18 - PubMed
  46. Eur J Epidemiol. 2010 Sep;25(9):603-5 - PubMed

Publication Types